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Brief CommunicationCombating Susceptibility
to Drug Resistance:
Lessons from HIV-1 Protease
minants of substrate specificity difficult to derive from
sequence alignment alone. By analyzing the crystal
structures of six substrates [6, 7] in complex with an
inactive (D25N) HIV-1 protease variant (Figure 1A), we
have developed a “substrate envelope” hypothesis: that
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364 Plantation Street substrate specificity for HIV-1 protease is based not on
a particular amino acid sequence, but on a conservedWorcester, Massachusetts 01605
shape. This shape, or envelope, is defined by the over-
lapping volume occupied by the substrates within the
active site of HIV-1 protease (Figure 1B). HIV-1 proteaseSummary
likely recognizes a particular sequence as a substrate
in part due to the ability of that sequence to adopt thisDrug resistance is a major obstacle in modern medi-
cine. However, resistance is rarely considered in drug shape by a combination of packing of the substrate’s
side chains and rearrangements of the substrate’sdevelopment and may inadvertently be facilitated, as
many designed inhibitors contact residues that can backbone.
All currently prescribed HIV-1 protease inhibitors aremutate to confer resistance, without significantly im-
pairing function. Contemporary drug design often ig- competitive active site inhibitors. Thus, for drug resis-
tance to occur, it would seem necessary for the se-nores the detailed atomic basis for function and pri-
marily focuses on disrupting the target’s activity, quences of the substrate cleavage sites to dramatically
coevolve with the protease to attain drug resistancewhich is necessary but not sufficient for developing a
robust drug. In this study, we examine the impact of while maintaining a replicating and infectious virus. This
coevolution would be expected, as the competitive ac-drug-resistant mutations in HIV-1 protease on sub-
strate recognition and demonstrate that most primary tive site inhibitors would likely interact with the same
residues that are necessary to recognize and cleaveactive site mutations do not extensively contact sub-
strates, but are critical to inhibitor binding. We propose substrates. However, this type of coevolution occurs
only within the occasional cleavage site [8-11]; coevolu-a general, structure-based strategy to reduce the
probability of drug resistance by designing inhibitors tion of the substrates with HIV-1 protease is the excep-
tion rather than the rule. The most frequent and well-that interact only with those residues that are essential
for function. characterized coevolution of a substrate with a drug
resistant mutation in the protease occurs when the P2
residues of the NC-p1 cleavage site mutates from anIntroduction
alanine to a valine in response to the V82A mutation.
Although other cases of coevolution between the sub-Drug resistance occurs when mutations in the target
protein allow the protein to retain function while no strates and protease exist, they appear to be relatively
rare; no comprehensive study has been performed onlonger being inhibited efficiently by the drug. In the case
of HIV-1 protease, drug resistance occurs when, even large numbers of viral sequences. Generally, HIV-1 pro-
tease manages to evolve drug resistance to active sitein the presence of protease inhibitors, the enzyme is
able to cleave the Gag and Pol polyproteins in at least inhibitors without strongly compromising substrate rec-
ognition.nine different locations, allowing viral maturation. At first
inspection, development of drug resistance for HIV-1
protease would appear to be particularly difficult, as
Results and Discussionall of the currently prescribed protease inhibitors are
competitive inhibitors that bind in the center of the active
The currently prescribed HIV-1 protease inhibitors aresite [1]. Nevertheless, many viable drug-resistant muta-
all chemically different [12, 13], relatively low moleculartions occur within patients due to the high replicative
weight compounds and can elicit different, yet over-rate of the virus [2], the infidelity of the reverse tran-
lapping, patterns of drug-resistant mutations [14-16].scriptase [3-5], and the selective pressure of protease
However, if we superimpose the structures of eight pro-inhibitor therapy on the evolution of the virus. The accu-
tease-inhibitor complexes, the volumes occupied by themulation of multiple drug-resistance mutations within
inhibitors overlap, significantly allowing the definition ofHIV-1 protease then renders current therapies inef-
an “inhibitor envelope” (Figure 1C). The inhibitors arefective.
much smaller than the substrates to maintain bioavail-To understand how drug resistance can occur while
ability and are, on average, a different shape than theretaining substrate recognition, we have focused on
substrates. Similar functional groups within the inhibi-substrate recognition by HIV-1 protease. The nine sub-
tors are often positioned at similar locations in the prote-strate sequences cleaved by the protease within the
ase active site. This overlap means that many of theviral polyproteins differ significantly, making the deter-
inhibitors contact the protease at the same residues
(Figure 1D). Overlaying the inhibitor envelope on the*Correspondence: celia.schiffer@umassmed.edu
1These authors contributed equally to this work. substrate envelope [7] (Figure 1E) results in several loca-
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Figure 1. Substrate and Inhibitor Envelopes of HIV-1 Protease
(A) The substrate envelope calculated with GRASP [26] from the overlapping van der Waals volume of four or more substrate peptides. The
colors of the substrate peptides are red, matrix-capsid; green, capsid-p2; blue, p2-nucleocapsid; cyan, p1-p6; magenta, reverse-transcriptase-
ribonucleaseH; and yellow, ribonucleaseH-integrase.
(B) The substrate envelope as it fits within the active site of HIV-1 protease. The -carbon trace is of the CA-p2 substrate peptide com-
plex [6].
(C) The inhibitor envelope calculated from overlapping van der Waals volume of five or more of eight inhibitor complexes. The colors of the
inhibitors are yellow, Nelfinavir (NFV); gray, Saquinavir (SQV); cyan, Indinavir (IDV); light blue, Ritonavir (RTV); green, Amprenavir (APV); magenta,
Lopinavir (LPV); blue, Atazanavir (ATV); and red, (TMC114).
(D) The inhibitor envelope as it fits within the active site of HIV-1 protease.
(E) Superposition of the substrate envelope (blue) with the inhibitor envelope (red). Residues that contact the inhibitors where the inhibitors
protrude beyond the substrate envelope and confer drug resistance when they mutate are labeled.
tions, specifically between the P3 and P2 subsites, We observe that those specific HIV-1 protease resi-
dues, which are contacted by the inhibitors where thewhere the inhibitor envelope protrudes beyond the sub-
strate envelope. These locations contact specific resi- inhibitors protrude from the substrate envelope, corre-
spond to the residues where most multi-drug-resistantdues in HIV-1 protease.
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when it mutates to a valine there is a decrease in van
der Waals contacts in each of the inhibitor complexes.
Nevertheless, the fact that most of the residues where
primary drug-resistant mutations occur are at sites
where the inhibitors protrude beyond the substrate en-
velope is not likely fortuitous. These residues are prime
sites for the evolution of drug-resistant mutations, as
they are at positions that will preferentially impact inhibi-
tor binding over substrate recognition. We previously
observed this mechanism of drug resistance by solving
and analyzing a series of substrate and inhibitor crystal
structures in complex with an HIV-1 protease variant
with the multi-drug resistant V82A mutation [17]. The
analysis presented here supports the assessment that
this mechanism for conferring resistance is a general
principle.
The inhibitor atoms that do not overlap with the sub-
strates are highlighted in Figure 3. Each inhibitor has
several atoms that are more than 1.4 A˚ from any sub-
strate atoms (Figure 3A). These atoms are color coded
by their average distance from any of the six substrates
(Figure 3B), and the protease residues with which they
make contact are listed. Atoms within each inhibitor
Figure 2. Active Site Region of HIV Protease that are more than 2.0 A˚ from any substrate necessarily
Residues that confer at least low-level resistance to three or more protrude from the envelope. The protease residues sur-
inhibitors are highlighted in large bold text. Indinavir [21] is shown
rounding the inhibitors can be grouped into two majorin yellow as an example of the interactions of these residues with
categories: residues that mutate and confer drug resis-an inhibitor. The orientation is in a similar orientation as seen in Fig-
tance and residues that very rarely mutate. Those thature1B. The figure was made with the graphics program MIDAS [25].
confer resistance are listed in Table 1. At residues G48,
I50, V82, and I84 there is clearly a high degree of overlap,
although the exact resistance profile varies depending
mutations occur (Figure 1E). The mutation L90M is the on the particular inhibitor. The remaining residues sur-
only mutation that confers high levels of drug resistance rounding the inhibitors rarely mutate and are likely cru-
yet does not make direct contact with the inhibitors, as cial to the protease’s structure or ability to recognize
it is located outside of the active site. Therefore, this and cleave substrates. These residues, with the very
mutation must confer resistance through another, or small number of HIV-infected patient isolates showing
indirect, mechanism. Figure 2 highlights those con- mutations at these sites in parentheses, are R8 (27), G27
tacted residues that confer at least low-level drug resis- (2), A28 (6), D29 (11), G49 (7), T80 (4), and P81 (1) from
tance to three or more inhibitors. For instance, mutation over 6300 isolates in the Stanford database [14, 15].
of I84, which is located in the center of the HIV-1 prote- Thus, resistance appears to have evolved at those resi-
ase active site, to a valine is the worst of the multi-drug- dues where HIV protease can best tolerate change while
resistant mutations (Table 1), strongly impacting the retaining the protease’s function to cleave substrates.
binding of all of the current protease inhibitors. However, Although the protease residues that mutate and con-
the degree of protrusion of inhibitors from the substrate fer drug resistance primarily contact inhibitor atoms,
envelope to contact residue 84 does not appear to ac- these residues also contact a few substrate atoms. How-
count for the site’s ability to confer multi-drug resis- ever, for the three drug-resistant mutations [14, 15] I50V,
tance. Rather, residue 84’s central location likely ac- V82A and I84V, where the size of the residue decreases
counts for its high degree of cross-resistance, since once it mutates, the inhibitors that are compromised
due to these mutations lose on average two more van
der Waals contacts than do the substrates. Usually, the
Table 1. Drug Resistance Conferring Residues which Contact loss of contact with the substrate is negligible and does
Inhibitors at Positions outside the Substrate Envelope not substantially alter its binding, since it represents a
relatively small percentage of the total surface area bur-High-Level Intermediate- Low-Level
Inhibitor Resistance1 Level Resistance1 Resistance1 ied on the protease by the substrate. However, in partic-
ular cases, a protease mutation may cause a particularNFV D30, I84 G48, V82
substrate to coevolve to preserve substrate recognition.SQV G48, I84 V82
RTV V82, I84 I50 G48 Such a mutation occurs at the rate-determining step in
IDV V82, I84 I47 G48 the processing of Gag, the nucleocapsid-p1 cleavage
APV I50, I84 V82 site [8-11]. We have recently discovered [18] that the
LPV V82 I47, I50, I84 G48 structural basis for this coevolution occurs when a key
ATV I50, I84 V82 G48
contact at the P1 Phe, which protrudes beyond the
1 Level of resistance as defined by the Stanford database [14, 15]. substrate envelope, is lost in the HIV protease complex
TMC114, which is still in clinical trials, does not yet have a pattern due to the protease mutation V82A. The substrate co-
of resistance.
evolves when the unusually small alanine at P2 mutates
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Figure 3. Inhibitor Atoms which Protrude be-
yond the Substrates
(A) Stereo superposition of six substrates
(yellow) and eight inhibitors (black and red).
The atoms within the inhibitors that are more
than 1.4 A˚ from substrate atoms are colored
in red.
(B) Eight inhibitors (NFV, SQV, IDV, RTV, APV,
LPV, ATV, and TMC114) are shown with their
atoms colored by their average distance from
substrate atoms. The gray (0–1.4 A˚), cyan
(1.4–2.0 A˚), red (2.0–2.5 A˚), orange (2.5–3.0 A˚),
yellow (3.0–3.5 A˚), and white (3.5–4.0 A˚) show
those atoms that are, on average, the furthest
from any substrate atom when the inhibitor
complexes are superimposed on the sub-
strate complexes of HIV-1 protease. Listed
near these atoms are the protease residues
within van der Waals contact, and those that
confer resistance to a particular inhibitor are
in bold (except for TMC114, for which the
resistance profile is not yet identified). The
figure was made with the graphics program
MIDAS [25].
to a more typically branched residue at this site, valine, into one possible means for circumventing drug resis-
tance. In analyzing the location of the residues of mostthereby likely restabilizing the resulting substrate prote-
ase complex. Such coevolution can happen if one sub- of the active site drug-resistant mutations in HIV prote-
ase, we find that these mutations usually occur wherestrate is impacted by a drug-resistant mutation, but if
six or more substrates are affected, it is unlikely that the inhibitors protrude beyond the substrate envelope.
Therefore, these residues are more important for in-all six substrates could simultaneously coevolve and
preserve viral function. hibitor binding than for substrate recognition. Drug
resistance thus occurs in a manner that retains sub-
strate recognition and protease activity. This analysisSignificance
implies that an inhibitor contained within the substrate
envelope, interacting only with the same residues thatBy exploring how a protein target such as HIV-1 prote-
ase functions in atomic detail, we have gained insights are necessary to recognize substrate, may be less
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